Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer ...

Catch up on all the biggest pharma news to hit the industry last month, spanning from new acquisitions, insights on the NHS ...

for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase ...

Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors to Roche's Genentech for an upfront cash payment of $850 million. Discover how AI is transforming the pharma commercial ...

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The purchase agreement was announced at Roche’s ...

has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast ...

A pair of cyberattacks against software maker CDK continues to impact thousands of car dealerships and has spurred threat actors to launch impersonation attacks. The CDK Global outage affecting ...

AUSTIN, Texas--(BUSINESS WIRE)--CDK, the leading automotive retail software provider, today announced a long-term extension of its agreement with AutoCanada Inc. (TSX: ACQ), a multi-location North ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...